Form 13F-HR TCG Crossover Management For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
August 15, 2022 2:53 PM EDT
The Securities and Exchange Commission has not necessarily reviewed
the information in this filing and has not determined if it is
accurate and complete.
The reader should not assume that the information is accurate
and complete.
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F
FORM 13F COVER PAGE
|
| OMB APPROVAL |
| OMB Number: |
3235-0006 |
| Expires: |
July 31, 2015 |
| Estimated average burden |
| hours per response: |
23.8 |
|
|
| Report for the Calendar Year or Quarter Ended: |
06-30-2022 |
| Check here if Amendment |
|
Amendment Number: |
|
| This Amendment (Check only one.): |
|
is a restatement. |
|
|
adds new holdings entries. |
| Institutional Investment Manager Filing
this Report: |
| Name: |
TCG Crossover Management, LLC |
| Address: |
705 High St. |
|
|
|
Palo Alto
,
CA94301
|
| Form 13F File Number: |
028-22283 |
The institutional investment manager filing this report and
the person by whom it is signed hereby represent that the person
signing the report is authorized to submit it, that all information
contained herein is true, correct and complete, and that it is
understood that all required items, statements, schedules, lists, and
tables, are considered integral parts of this form.
| Person Signing this Report on Behalf of
Reporting Manager: |
| Name: |
Craig Skaling |
| Title: |
CCO & CFO |
| Phone: |
415-260-2047 |
| Signature, Place, and Date of Signing: |
| /s/ Craig Skaling |
Palo Alto
,
CA
|
08-15-2022 |
| [Signature] |
[City, State] |
[Date] |
|
| Report Type (Check only one.): |
| X |
13F HOLDINGS REPORT. (Check here if all holdings of
this reporting manager are reported in this report.) |
|
|
13F NOTICE. (Check here if no holdings reported are in
this report, and all holdings are reported by other reporting
manager(s).) |
|
|
13F COMBINATION REPORT. (Check here if a portion of
the holdings for this reporting manager are reported in this
report and a portion are reported by other reporting manager(s).) |
| Form 13F Summary Page |
|
Report Summary: |
|
Number of Other Included
Managers: |
0 |
|
|
|
Form 13F Information Table Entry Total: |
22 |
|
Form 13F Information Table Value Total: |
235,414 |
|
(thousands) |
|
List of Other Managers Reporting for this Manager:
[If there are no entries in this list, omit this section.]
|
|
|
Form 13F File Number |
Name |
| List of Other Included
Managers: |
|
Provide a numbered list of the name(s) and Form 13F file number(s)
of all institutional investment managers with respect to which this
report is filed, other than the
manager filing this report.
|
|
[If there are no entries in this list, state “NONE” and omit the
column headings and list entries.]
|
|
No. |
Form 13F File Number |
Name |
The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
The reader should not assume that the information is
accurate and complete.
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F
FORM 13F INFORMATION TABLE
|
| OMB APPROVAL |
| OMB Number: |
3235-0006 |
| Expires: |
July 31, 2015 |
| Estimated average
burden |
| hours per response:
|
23.8 |
|
|
| COLUMN 1 |
COLUMN 2 |
COLUMN 3 |
COLUMN 4 |
COLUMN 5 |
COLUMN 6 |
COLUMN 7 |
COLUMN 8 |
|
|
|
VALUE |
SHRS OR |
SH/ |
PUT/ |
INVESTMENT |
OTHER |
VOTING AUTHORITY |
| NAME OF ISSUER |
TITLE OF CLASS |
CUSIP |
(x$1000) |
PRN AMT |
PRN |
CALL |
DISCRETION |
MANAGER |
SOLE |
SHARED |
NONE |
| CymaBay Therapeutics, Inc. |
COMMON STOCK |
23257D103 |
17,421 |
5,905,400 |
SH |
|
SOLE |
|
5,905,400 |
0 |
0 |
| Cogent Biosciences, Inc. |
COMMON STOCK |
19240Q201 |
31,399 |
3,481,042 |
SH |
|
SOLE |
|
3,481,042 |
0 |
0 |
| Chinook Therapeutics, Inc. |
COMMON STOCK |
16961L106 |
13,930 |
796,460 |
SH |
|
SOLE |
|
796,460 |
0 |
0 |
| Magenta Therapeutics, Inc. |
COMMON STOCK |
55910K108 |
2,549 |
2,124,122 |
SH |
|
SOLE |
|
2,124,122 |
0 |
0 |
| Zai Lab LTD-ADR |
COMMON STOCK |
98887Q104 |
3,295 |
95,000 |
SH |
|
SOLE |
|
95,000 |
0 |
0 |
| Aclaris Therapeuitics, Inc. |
COMMON STOCK |
00461U105 |
15,983 |
1,144,939 |
SH |
|
SOLE |
|
1,144,939 |
0 |
0 |
| Elevation Oncology, Inc. |
COMMON STOCK |
28623U101 |
777 |
555,000 |
SH |
|
SOLE |
|
555,000 |
0 |
0 |
| Aerovate Therapeutics, Inc. |
COMMON STOCK |
008064107 |
13,904 |
889,572 |
SH |
|
SOLE |
|
889,572 |
0 |
0 |
| Iveric Bio, Inc. |
COMMON STOCK |
46583P102 |
28,035 |
2,914,250 |
SH |
|
SOLE |
|
2,914,250 |
0 |
0 |
| Viridian Therapeutics Inc |
COMMON STOCK |
92790C104 |
15,203 |
1,314,000 |
SH |
|
SOLE |
|
1,314,000 |
0 |
0 |
| Tyra Biosciences, Inc. |
COMMON STOCK |
90240B106 |
6,409 |
896,418 |
SH |
|
SOLE |
|
896,418 |
0 |
0 |
| Alpine Immune Sciences, Inc. |
COMMON STOCK |
02083G100 |
4,921 |
578,260 |
SH |
|
SOLE |
|
578,260 |
0 |
0 |
| Akouos, Inc. |
COMMON STOCK |
00973J101 |
6,332 |
1,350,006 |
SH |
|
SOLE |
|
1,350,006 |
0 |
0 |
| Merus N.V. |
COMMON STOCK |
N5749R100 |
6,792 |
300,000 |
SH |
|
SOLE |
|
300,000 |
0 |
0 |
| Entrada Therapeutics, Inc. |
COMMON STOCK |
29384C108 |
8,084 |
663,694 |
SH |
|
SOLE |
|
663,694 |
0 |
0 |
| Pardes Biosciences, Inc. |
COMMON STOCK |
69945Q105 |
181 |
59,039 |
SH |
|
SOLE |
|
59,039 |
0 |
0 |
| Kura Oncology, Inc. |
COMMON STOCK |
50127T109 |
21,403 |
1,167,642 |
SH |
|
SOLE |
|
1,167,642 |
0 |
0 |
| AnaptysBio, Inc. |
COMMON STOCK |
032724106 |
1,188 |
58,515 |
SH |
|
SOLE |
|
58,515 |
0 |
0 |
| Tango Therapeutics, Inc. |
COMMON STOCK |
87583X109 |
5,310 |
1,172,250 |
SH |
|
SOLE |
|
1,172,250 |
0 |
0 |
| Geron Corporation |
COMMON STOCK |
374163103 |
23,399 |
15,096,342 |
SH |
|
SOLE |
|
15,096,342 |
0 |
0 |
| MoonLake Immunotherapeutics |
COMMON STOCK |
61559X104 |
5,250 |
1,000,000 |
SH |
|
SOLE |
|
1,000,000 |
0 |
0 |
| 89bio, Inc. |
COMMON STOCK |
282559103 |
3,649 |
1,133,196 |
SH |
|
SOLE |
|
1,133,196 |
0 |
0 |
Tweet
Share
E-mail
